Regard
AI clinical insights platform that surfaces patient history context and documentation before physician review.
Last updated: June 5, 2026
Back to directoryFDA-cleared clinical surveillance platform that uses machine-learning models to surface adult ICU deterioration risk and workflow notifications.
Hospitals evaluating predictive surveillance for high-acuity units where ICU teams can govern alert routing, escalation, and local performance monitoring.
Compare within workflow: Clinical operations and revenue cycle · comparison shortlist · source index
Product-specific review. These product-specific signals summarize what the cited sources imply before treating CLEW ICU as safe for a local clinical, operational, or research workflow.
| Regulatory / FDA | Treat as high-risk medical-device software and match deployment to the FDA-cleared indication, adult critical-care setting, prediction outputs, labeling, and change-control boundaries for K233216. |
|---|---|
| Privacy | Review EHR, bedside-device, tele-ICU, and cloud data flows; BAA terms; PHI retention; access controls; audit logs; security posture; support access; and whether privacy materials are website-only or customer-contract specific. |
| Evidence | Do not rely on clearance alone; validate local performance, alert thresholds, sensitivity, PPV, low-risk labeling, false negatives, false positives, workflow response, and subgroup performance. |
| Workflow | Best governed by ICU, tele-ICU, rapid-response, biomedical, informatics, and patient-safety owners with defined escalation rules, override review, downtime plans, and post-deployment monitoring. |
CLEW describes CLEW ICU as an AI-driven clinical surveillance platform for high-acuity care with FDA-cleared class II predictive models; FDA records list K233216 for the CLEWICU System as a medium-term adjunctive predictive cardiovascular indicator with a January 13, 2024 substantial-equivalence decision.
Not for: Standalone diagnosis, autonomous treatment decisions, non-ICU populations outside the cleared intended use, or deployment without local validation and clinician response protocols.
Use these links to confirm current claims, terms, regulatory status, pricing, and deployment requirements.